Most Popular - Following the Phase III failure of Oncothyreon’s lead candidate Stimuvax, we see some value remaining in the oncology developer. The company has a few options … Continue Reading
Read nowMost Popular - On Monday, we wrote that MethylGene, a relative unknown in the industry, is poised to climb after a recent financing. While the stock remains flat … Continue Reading
Read nowMost Popular - Between Keryx and its Japanese partner JT Torii, four clinical trials for lead candidate Zerenex are set to report data over the coming months. The … Continue Reading
Read nowLong Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) updated investors Thursday morning on both its Zerenex development program and its 3Q financials, reiterating that pivotal Phase 3 data for the … Continue Reading
Read nowMost Popular - PropThink published its latest report on Keryx Biopharmaceuticals last week, and on Monday we followed up with some technical discussion. We also included QCOR in … Continue Reading
Read nowRecap - A patent extension for Folotyn added five years to the drug’s market exclusivity and elicited a rally in Spectrum (SPPI) on Monday, but the news … Continue Reading
Read nowLong Ideas - Shares of Aeterna Zentaris (NASDAQ:AEZS) are strong Thursday morning after a Buy initiation from Roth Capital with a $1.75 price target, more than double its … Continue Reading
Read now